CITY VIEW GREEN HOLDINGS INC. CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2024 (EXPRESSED IN CANADIAN DOLLARS) (UNAUDITED)

Notice To Reader

The accompanying unaudited condensed interim consolidated financial statements of City View Green Holdings Inc. (the "Company") have been prepared by and are the responsibility of management. The unaudited condensed interim consolidated financial statements have not been reviewed by the Company's auditors.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Financial Position (Expressed in Canadian Dollars) Unaudited

| As at | S | September 30, 2024 | | |
|--|----|-----------------------|----|--------------|
| ASSETS | | | | |
| Current assets | | | | |
| Cash | \$ | 77 | \$ | 343 |
| Amounts receivable (note 5) | | 1,517 | | 3,503 |
| Total assets | \$ | 1,594 | \$ | 3,846 |
| DEFICIENCY AND LIABILITIES | | | | |
| Current liabilities | | | | |
| Accounts payable and accrued liabilities (note 8) | \$ | 2,453,150 | \$ | 2,234,404 |
| Promissory notes payable (note 9) | | 595,614 | | 557,650 |
| Loans payable (note 10) | | 872,552 | | 836,230 |
| Due to related parties (note 14) | | 75,640 | | 104,689 |
| Total liabilities | | 3,996,956 | | 3,732,973 |
| Shareholders' deficiency | | | | |
| Share capital (note 11) | | 32,270,906 | | 32,206,706 |
| Contributed surplus (note 12) | | 8,155,453 | | 8,124,653 |
| Equity portion of convertible loan payable (note 10) | | 42,917 | | 42,917 |
| Deficit | | (44,464,638) | | (44,103,403) |
| Total shareholders' deficiency | • | (3,995,362) | | (3,729,127) |
| Total shareholders' deficiency and liabilities | \$ | 1,594 | \$ | 3,846 |

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Nature of operations and going concern (note 1) Subsequent events (note 16)

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Loss and Comprehensive Loss (Expressed in Canadian Dollars) Unaudited

| | | ree Months Ended ptember 30, 2024 | | ree Months Ended ptember 30, 2023 | | ne Months Ended ptember 30, 2024 | | ne Months Ended stember 30, 2023 |
|--|----|--|----|--|----|---|----|---|
| Revenue | \$ | - | \$ | - | \$ | - | \$ | 8,582 |
| Expenses | | | | | | | | |
| Consulting (note 14) | | 56,250 | | 66,750 | | 265,362 | | 217,572 |
| General and administration | | 36,281 | | 111,087 | | 138,522 | | 221,732 |
| Interest on loans and promissory | | , | | , | | , | | , |
| notes payable (notes 9 and 10) | | 24,887 | | 23,183 | | 74,286 | | 67,124 |
| Professional fees | | 11,350 | | 25,392 | | 63,338 | | 105,361 |
| Rent | | - ^ | | <u>-</u> | | 11,928 | | 1,550 |
| Depreciation (note 7) | | - | | 74,830 | | - | | 224,490 |
| Accretion (note 10) | | - | | - | | - | | 26,334 |
| Debt issue costs (notes 10 and 13) | | - | | 3,500 | | - | | 3,500 |
| Total expenses | | 128,768 | | 304,742 | | 553,436 | | 867,663 |
| Net loss before interest and undernoted items | | (128,768) | | (304,742) | | (553,436) | | (859,081) |
| Gain on sale of property and equipment | | - | | _ | | 172,701 | | _ |
| Other income | | 19,500 | | - | | 19,500 | | - |
| Interest income (note 6) | | - | | 9,226 | | - | | 26,414 |
| Gain on debt settlement (note 11) | | - | | - | | - | | 12,500 |
| Net loss and comprehensive loss for the period | \$ | (109,268) | \$ | (295,516) | \$ | (361,235) | \$ | (820,167) |
| Basic and diluted net comprehensive | | | | | | | | |
| loss per share (note 15) | \$ | (0.00) | \$ | (0.00) | \$ | (0.00) | \$ | (0.00) |
| Weighted average number of common shares outstanding - basic and diluted | 3 | 56,087,960 | 34 | 46,587,960 | 3 | 50,124,456 | 34 | 41,640,463 |

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Changes in Shareholders' Equity (Deficiency) (Expressed in Canadian Dollars) Unaudited

| | Share | есар | oital | | | | | | | | |
|--|---------------------|------|---|----|---------------------|----|---------------------|----|---|--------------------|-------------|
| | Number of shares | | Amount | | Shares to be issued | C | Contributed surplus | of | uity portion convertible an payable | Deficit | Total |
| Balance, December 31, 2022 | 321,254,625 | \$: | 31,831,706 | \$ | 257,223 | \$ | 8,113,253 | \$ | 39,500 | \$ (41,654,811) \$ | (1,452,629) |
| Shares issued for cash | 24,833,335 | | 372,500 | | (100,000) | | - | | - | - | 272,500 |
| Shares issued for debt settlement | 500,000 | | 2,500 | | - | | - | | - | - | 2,500 |
| Warrants issued for debt issue costs | - | | - | | - | | 11,400 | | - | - | 11,400 |
| Net loss and comprehensive loss for the period | - | | - | | - | | - | | - | (820,167) | (820,167) |
| Balance, September 30, 2023 | 346,587,960 | \$: | 32,206,706 | \$ | 157,223 | \$ | 8,124,653 | \$ | 39,500 | \$ (42,474,978) \$ | (1,946,896) |
| Balance, December 31, 2023 | 346,587,960 | \$: | 32,206,706 | \$ | - | \$ | 8,124,653 | \$ | 42,917 | \$ (44,103,403) \$ | (3,729,127) |
| Shares issued for cash | 9,500,000 | - | 95,000 | - | - | | - | • | - | - | 95,000 |
| Fair value of warrants | - | | (30,800) | | - | | 30,800 | | - | - | - ′ |
| Net loss and comprehensive loss | | | (,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, | | | | ,,,,,,, | | | | |
| for the period | - | | - | | - | | - | | - | (361,235) | (361,235) |
| Balance, September 30, 2024 | 356,087,960 | \$: | 32,270,906 | \$ | - | \$ | 8,155,453 | \$ | 42,917 | \$ (44,464,638) \$ | (3,995,362) |

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

City View Green Holdings Inc.
Condensed Interim Consolidated Statements of Cash Flows
(Expressed in Canadian Dollars) Unaudited

| | Nine Months Ended September 30, 2024 | Nine Months Ended September 30, 2023 |
|--|---|---|
| Operating activities | | |
| Net loss for the period | \$ (361,235) | \$ (820,167) |
| Adjustments for: | | |
| Depreciation | - | 224,490 |
| Accrued interest | 74,286 | 40,710 |
| Debt issue costs | - | 3,500 |
| Accretion | - | 26,334 |
| Gain on debt settlement | - | (12,500) |
| Changes in non-cash working capital items: | | |
| Amounts receivable | 1,986 | 42,460 |
| Prepaid expenses | - | 10,888 |
| Accounts payable and accrued liabilities | 218,746 | 174,346 |
| Net cash used in operating activities | (66,217) | (309,939) |
| Financing activities | | |
| Proceeds from issuance of shares | 95,000 | 272,500 |
| Proceeds from loan payable | - | 100,000 |
| Advances to related parties | (29,049) | (60,698) |
| Net cash provided by financing activities | 65,951 | 311,802 |
| Net change in cash for the period | (266) | 1,863 |
| Cash (bank overdraft), beginning of period | 343 | (494) |
| Cash, end of period | \$ 77 | \$ 1,369 |

The accompanying notes to the unaudited condensed interim consolidated financial statements are an integral part of these statements.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

1. Nature of operations and going concern

City View Green Holdings Inc. ("City View", and, with its subsidiary, the "Company") was incorporated pursuant to the Canada Business Corporations Act on February 5, 2008. The Company continued into British Columbia from the jurisdiction of Canada, under the *British Columbia Business Corporations Act*, on February 18, 2011. On February 27, 2019, the Company completed a reverse take-over business combination with 2590672 Ontario Inc. ("2590672 Ontario") wherein the Company acquired 100% of the issued and outstanding common shares of 2590672 Ontario and began trading on the Canadian Securities Exchange (the "CSE") under the symbol "CVGR". The Company's registered office is located at 345 Danforth Avenue, Toronto, Ontario, M4K 1N7.

The Company formulates, produces and sells cannabis edibles and related products.

The unaudited condensed interim consolidated financial statements have been prepared using accounting policies applicable to a going concern, which contemplates the realization of assets and settlement of liabilities in the normal course of business as they become due. As at September 30, 2024, the Company has an accumulated deficit of \$44,464,638 (December 31, 2023 - \$44,103,403) and a working capital deficiency of \$3,995,362 (December 31, 2023 - working capital deficiency of \$3,729,127), and for the year then ended, the Company incurred a net loss of \$361,235 (nine months ended September 30, 2023 - net loss of \$820,167). In April 2024, the Company announced that it was exiting the retail cannabis space. These conditions raise material uncertainties which cast significant doubt about the Company's ability to continue as a going concern.

The Company's ability to continue as a going concern is dependent upon its ability to generate future profitable operations and/or to obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. While the Company is continuing its best efforts to achieve the above plans, there is no assurance that any such activity will generate funds for operations. The unaudited condensed interim consolidated financial statements do not reflect adjustments to the carrying values and classification of assets and liabilities that might be necessary should the Company be unable to continue as a going concern, and such adjustments may be material.

2. Basis of presentation

The Company applies International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and interpretations issued by the International Financial Reporting Interpretations Committee ("IFRIC"). These unaudited condensed interim consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting. Accordingly, they do not include all of the information required for full annual financial statements required by IFRS as issued by IASB and interpretations issued by IFRIC.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRSs issued and outstanding as of November 29, 2024, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual financial statements as at and for the year ended December 31, 2023. Any subsequent changes to IFRS that are given effect in the Company's annual financial statements for the year ending December 31, 2024 could result in restatement of these unaudited condensed interim consolidated financial statements.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

3. Significant accounting judgments, estimates and assumptions

The preparation of the consolidated financial statements using accounting policies consistent with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. The preparation of the consolidated financial statements also requires management to exercise judgment in the process of applying the accounting policies.

Critical accounting estimates

Share-based compensation – management is required to make a number of estimates when determining the compensation expense resulting from share-based transactions, including the forfeiture rate and expected life of the instruments.

Warrants – management is required to make a number of estimates when measuring the value of warrants including expected life of the instruments.

Critical judgments in applying accounting policies

Income taxes – measurement of income taxes payable and deferred income tax assets and liabilities requires management to make judgments in the interpretation and application of the relevant tax laws. The actual amount of income taxes only become final upon filing and acceptance of the tax return by the relevant authorities, which occurs subsequent to the issuance of the consolidated financial statements.

Going concern – the assessment of the Company's ability to continue as a going concern involves judgment regarding future funding available for its operations and working capital requirements as discussed in note 1.

4. Capital risk management

The Company manages its capital with the following objectives:

- to ensure sufficient financial flexibility to achieve the ongoing business objectives including funding of future growth opportunities; and
- to maximize shareholder return through enhancing the share value.

The Company monitors its capital structure and makes adjustments according to market conditions in an effort to meet its objectives given the current outlook of the business and financial markets in general. The Company may manage its capital structure by issuing new shares, repurchasing outstanding shares, or adjusting spending. The capital structure is reviewed by management and the Board of Directors on an ongoing basis.

The Company considers its capital structure to consist of share capital, shares to be issued, contributed surplus, equity portion of convertible loan payable, and deficit, which at September 30, 2024 totaled a deficiency of \$3,995,362 (December 31, 2023 - deficiency of \$3,729,127). The Company reviews its working capital and forecasts its future cash flows based on operating expenditures, and other investing and financing activities. Selected information is provided to the Board of Directors of the Company. The Company is not subject to any capital requirements imposed by a lending institution.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

5. Amounts receivable

| | Se | As at September 30, 2024 | | | |
|--|----|--------------------------------|----|-------|--|
| Sales tax recoverable Amounts receivable | \$ | 347 1,170 | \$ | 3,503 | |
| | \$ | 1,517 | \$ | 3,503 | |

6. Promissory note receivable

On March 5, 2019, the Company entered into a loan agreement in the amount of \$200,000 with 11103016 Canada Inc. ("11103016 Canada"). The loan is secured by 11103016 Canada's inventory and equipment, and bears interest rate of Prime Bank Rate plus 5% per annum, calculated monthly not in advance. The loan is repayable on or before March 5, 2020. The Company loaned an additional \$100,000 to 11103016 Canada in August 2019. On March 5, 2020, the Company extended the repayment date of the loan to December 31, 2020. In April 2021, the repayment date was extended to December 31, 2021, and in April 2022, the repayment date was further extended to December 31, 2022.

During the year ended December 31, 2023, the Company determined that the promissory note was not recoverable and recorded an impairment loss of \$427,779.

7. Plant and equipment

| Cost | Equipment |
|---|-------------------------------------|
| Balance, December 31, 2022 Impairment (i) Balance, December 31, 2023 and September 30, 2024 | \$ 1,496,602 (1,496,602) \$ - |
| Accumulated depreciation | Ψ |
| Balance, December 31, 2022 Depreciation for the year Impairment (i) | \$ 433,897 299,320 (733,217) |
| Balance, December 31, 2023 and September 30, 2024 | \$ - |
| Carrying value | |
| Balance, December 31, 2023 | \$ - |
| Balance, September 30, 2024 | \$ - |

⁽i) For the year ended December 31, 2023, the Company determined it will not be able to recover any amount from its equipment. As a result, the Company recorded an impairment on property and equipment of \$763,385.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

8. Accounts payable and accrued liabilities

Accounts payable and accrued liabilities of the Company are principally comprised of amounts outstanding for purchases relating to general operating activities.

| | Se | As at eptember 30, 2024 | D | As at ecember 31, 2023 |
|--|----|-------------------------|----|------------------------|
| Accounts payable Accrued liabilities | \$ | 1,377,808 1,075,342 | \$ | 1,277,561 956,843 |
| Total accounts payable and accrued liabilities | \$ | 2,453,150 | \$ | 2,234,404 |

9. Promissory notes payable

| | Quinsam (i) Ther | | herma (ii) | | Total | |
|--|------------------|-------------------|------------|-------------------|-------|-------------------|
| Balance, December 31, 2022 Interest accrued | \$ | 293,790 30,600 | \$ | 213,315 19,945 | \$ | 507,105 50,545 |
| Balance, December 31, 2023 | | 324,390 | | 233,260 | | 557,650 |
| Interest accrued | | 22,950 | | 15,014 | | 37,964 |
| Balance, September 30, 2024 | \$ | 347,340 | \$ | 248,274 | \$ | 595,614 |

(i) In August 2021, the Company obtained a \$225,000 secured loan from Quinsam Capital Corporation ("Quinsam"). The loan is repayable by December 31, 2021, bears interest at 10% per annum, and is secured by the Company's assets.

In connection therewith, the Company issued 750,000 warrants to Quinsam. Each warrant is exercisable for one common share of the Company at a price of \$0.15 per share for a period of 2 years. The 750,000 warrants were valued at \$37,300 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 0.47%; dividend yield - 0%; expected stock volatility - 199% and an expected life of 2 years.

In April 2022, the Company extended the repayment date to December 31, 2022. In consideration, the Company agreed to issue 500,000 shares of the Company to Quinsam. As a result, \$15,000 was expensed to debt issue cost.

During the year ended December 31, 2022, the Company obtained an additional \$30,000 loan from Quinsam.

In April 2023, the repayment date was extended to December 31, 2023. In April 2024, the repayment date was further extended to December 31, 2024.

As at September 30, 2024, the Company owed \$347,340 (December 31, 2023 - \$324,390) including accrued interest.

(ii) On May 2, 2022, the Company entered into a consulting agreement for services with Therma Bright Inc. ("Therma"), a company with common management and directors, to develop a pain formulation containing CBD for use with Therma's product portfolio. As a part of the agreement, the Company issued a promissory note in the amount of \$200,000 to Therma. The note is non-secured, bears interest of 10% per annum and is due on May 2, 2024. As at September 30, 2024, the Company owed \$248,274 (December 31, 2023 - \$233,260) including accrued interest.

City View Green Holdings Inc.
Notes to Condensed Interim Consolidated Financial Statements
Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) **Unaudited**

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

10. Loans payable

| | LOC A | Agreement (| (i) | CEBA (ii) | Total |
|--|-------|-------------|-----|-----------|---------------|
| Balance, December 31, 2022 | \$ | 625,730 | \$ | 40,000 | \$ 665,730 |
| Loan advanced | | 100,000 | | - | 100,000 |
| Equity portion of convertible loan payable | | (3,417) | | - | (3,417) |
| Interest accrued | | 44,166 | | - | 44,166 |
| Accretion | | 29,751 | | - | 29,751 |
| Balance, December 31, 2023 | | 796,230 | | 40,000 | 836,230 |
| Interest accrued | | 36,322 | | - | 36,322 |
| Balance, September 30, 2024 | \$ | 832,552 | \$ | 40,000 | \$ 872,552 |

(i) In 2020, the Company entered into a revolving line of credit (the "LOC") agreement with a third party lender (the "Lender"), whereby the Company can obtain \$1,500,000 of revolving line of credit financing facility to be used exclusively for the purchase of the Company's business related equipment, deposits for construction work and tenant's improvements on the Company's Brantford facility, or for security, rental payments, taxes and insurance related thereto. Funds advanced under the LOC are non-secured and bore interest at a rate of 10% per annum.

The LOC was to terminate on April 30, 2022 and bear interest at a rate of 7% per annum.

In September 2022, the LOC was amended. Under the terms of the amendment, the Lender may advance up to an additional \$500,000 under the LOC by December 15, 2022, upon certain conditions being met. The Lender has the right at any time until maturity to elect, in its sole discretion, to convert all or any portion of the outstanding amount into fully paid as non-assessable shares at a price of \$0.05 per share. The LOC was amended to terminate on June 30, 2023. The Company bifurcated \$39,500 to equity and the remaining balance to the carrying value of the loan.

On June 30, 2023, the LOC was amended to terminate on December 31, 2023. In connection with the amendment, the Company issued the Lender 3,250,000 share purchase warrants of the Company. The warrants expired on December 31, 2023 and were each exercisable for one common share of the Company at a price of \$0.10 per share. The 3,250,000 warrants were valued at \$3,500 as estimated using the Black-Scholes model for pricing options under the following assumptions: risk free interest rate - 4.81%; dividend yield - 0%; expected stock volatility - 352% and an expected life of 4 months.

In August 2023, the Lender advanced an additional \$100,000. The Company bifurcated \$3,417 to equity and the remaining balance to the carrying value of the loan.

For the three and nine months ended September 30, 2023, the Company recognized accretion expense of \$nil and \$26,334, respectively.

In April 2024, the LOC was amended to terminate on December 31, 2024.

(ii) In April 2020, the Company received \$40,000 under the Canada Emergency Business Account (CEBA) program. 25% of the loan was forgivable if repaid by December 31, 2022. The loan accrues no interest until December 31, 2023 and must be repaid by December 31, 2023. The forgiveness repayment date has been extended to January 18, 2024 for eligible CEBA loan holders in good standing. If the loan remains outstanding on January 19, 2024, it will convert to a non-amortizing term loan with full repayment due on December 31, 2026. Repayment of CEBA on or before the due date will result in loan forgiveness of 25% (up to \$10,000). The entire balance of \$40,000 is due and outstanding as at September 30, 2024.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

11. Share capital

(a) Authorized share capital

Unlimited number of common shares, with no par value.

(b) Common shares issued

| | Number of common shares | Amount |
|--|-------------------------------|--------------------------|
| Polance December 21, 2022 | | |
| Balance, December 31, 2022 Common shares issued for cash (i)(ii) | 24,833,335 | \$ 31,831,706 372,500 |
| Common shares issued for debt settlement (iii) | 500,000 | 2,500 |
| Balance, September 30, 2023 and December 31, 2023 | 346,587,960 | \$ 32,206,706 |
| Common shares issued for cash (iv) | 9,500,000 | 95,000 |
| Fair value of warrants (iv) | - | (30,800) |
| Balance, September 30, 2024 | 356,087,960 | \$ 32,270,906 |

- (i) On February 17, 2023, the Company closed the first tranche of a non-brokered private placement, pursuant to which it issued 21,666,668 common shares at \$0.015 per share for aggregate gross proceeds of \$325,000, of which \$100,000 proceeds were from the shares to be issued recorded in 2022. A director of the Company subscribed for 3,333,334 shares for \$50,000.
- (ii) On March 20, 2023, the Company closed the second and final tranche of its non-brokered private placement, pursuant to which it issued 3,166,667 common shares at \$0.015 per share for aggregate gross proceeds of \$47,500.
- (iii) On May 1, 2023, the Company issued 500,000 common shares to a creditor of the Company to settle an aggregate debt of \$15,000. The common shares issued had a deemed price of \$0.005 based on the fair value and as a result, the Company recognized a gain on settlement of debt of \$12,500.
- (iv) On June 20, 2024, the Company closed the first tranche of a non-brokered private placement, pursuant to which it issued 9,500,000 units at \$0.01 per unit for aggregate gross proceeds of \$95,000. Each unit consisted of one common share of the Company and one half share purchase warrant. Each whole warrant entitles the holder to purchase one common share of the Company at a price of \$0.05 per share for a period of 3 years from the closing date, except that, from and after the date that is one year after the closing date, if the average closing price of the Company's common shares on the CSE is equal to or exceeds \$0.055 during any 10 trading day period, then the Company may anytime thereafter accelerate the expiry date of the warrants to the date that is 30 days following the date on which the Company issues notice to all the warrant holders of the new expiry date. A director of the Company subscribed for 1,500,000 units for \$15,000.

The 4,750,000 warrants issued were assigned a value of \$30,800 using the Black-Scholes valuation model using the following assumptions: unit price of \$0.01, weighted average risk-free rate of return of 3.74%, expected volatility of 275% based on historical trends, dividend yield of 0%, and expected life of 3 years.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

12. Stock options

The Company has a Share Option Plan (the "Plan") under which it is authorized to grant options to purchase common shares of the Company to directors, senior officers, employees and/or consultants of the Company. The aggregate number of shares of the Company which may be issued and sold under the Plan may not exceed 15% of the total number of common shares issued and outstanding from time to time. Share options are granted with a maximum term of ten years with vesting terms at the discretion of the Board of Directors.

| | Number of stock options | Weighted average exercise price | | |
|---|---------------------------|---------------------------------------|------|--|
| Balance, December 31, 2022 | 32,009,732 | \$ | 0.21 | |
| Expired Balance, September 30, 2023 and December 31, 2023 | (1,166,400) 30,843,332 | \$ | 0.38 | |
| Forfeited | (1,150,000) | • | 0.11 | |
| Expired | (10,823,332) | | 0.39 | |
| Balance, September 30, 2024 | 18,870,000 | \$ | 0.11 | |

The following table reflects the actual stock options issued and outstanding as of September 30, 2024:

| Expiry date | Exercise price (\$) | Weighted average remaining contractual life (years) | Number of options outstanding | Number of options vested (exercisable) | |
|---------------------|---------------------|--|-------------------------------|---|--|
| October 4, 2024 (i) | 0.15 | 0.01 | 2,950,000 | 2,950,000 | |
| December 22, 2024 | 0.10 | 0.23 | 3,000,000 | 3,000,000 | |
| March 16, 2025 | 0.10 | 0.46 | 500,000 | 500,000 | |
| September 14, 2025 | 0.10 | 0.96 | 12,220,000 | 12,220,000 | |
| October 7, 2025 | 0.10 | 1.02 | 200,000 | 200,000 | |
| | 0.11 | 0.68 | 18,870,000 | 18,870,000 | |

⁽i) Subsequent to September 30, 2024, 2,950,000 stock options expired unexercised.

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

13. Warrants

| | Number of warrants | Weighted average exercise price | | |
|---|---|---------------------------------------|----------------------|--|
| Balance, December 31, 2022 Issued (i)(ii) Expired | 36,041,785 4,000,000 (30,748,214) | \$ | 0.08 0.10 0.07 | |
| Balance, September 30, 2023 | 9,293,571 | \$ | 0.12 | |
| Balance, December 31, 2023 Issued (iii) Expired | 3,350,000 4,750,000 (3,350,000) | \$ | 0.12 0.05 0.12 | |
| Balance, September 30, 2024 | 4,750,000 | \$ | 0.05 | |

- (i) During the nine months ended September 30, 2023, the Company issued 750,000 warrants in connection with a secured loan. The warrants expired unexercised.
- (ii) On August 25, 2023, the Company issued 3,250,000 warrants in connection with the amendment of the LOC (see note 10(i)). The warrants expired unexercised.
- (iii) During the nine months ended September 30, 2024, the Company issued an aggregate of 4,750,000 warrants (nine months ended September 30, 2023 nil warrants) as a part of its non-brokered private placements. See note 11.

The following table reflects the warrants issued and outstanding as of September 30, 2024:

| Expiry date | Exercise price (\$) | Warrants outstanding | | | | |
|---------------|---------------------|-------------------------|--|--|--|--|
| June 20, 2027 | 0.05 | 4,750,000 | | | | |

Notes to Condensed Interim Consolidated Financial Statements Three and Nine Months Ended September 30, 2024 (Expressed in Canadian Dollars) Unaudited

14. Related party balances and transactions

Related parties include key management being the Company's executive officers, the Board of Directors, close family members and enterprises that are controlled by these individuals as well as certain persons performing similar functions. The following related party transactions were conducted in the normal course of operations and were made on an arm's length basis:

| | Ended | | Three Months Ended September 30, 2023 | | Nine Months Ended September 30, 2024 | | Ended | |
|---------------------------------|-------|------------------|--|------------------|---|-------------------|-------|-------------------|
| Consulting Professional fees | \$ | 56,250 10,990 | \$ | 56,250 10,992 | \$ | 168,750 35,590 | \$ | 168,750 47,521 |
| | \$ | 67,240 | \$ | 67,242 | \$ | 204,340 | \$ | 216,271 |

As at September 30, 2024, \$990,529 (December 31, 2023 - \$745,058) included in accounts payable and accrued liabilities was payable to key management personnel.

As at September 30, 2024, the directors of the Company advanced a total of \$75,640 (December 31, 2023 - \$104,689). The advance is non-interest bearing and repayable on demand.

The Company issued a promissory note in the amount of \$200,000 to Therma, a company with common management and directors. See note 9(ii).

15. Loss per share

For the three and nine months ended September 30, 2024, basic and diluted loss per share has been calculated based on the loss attributable to common shares of \$109,268 and \$361,235, respectively (2023 - \$295,516 and \$820,167, respectively) and weighted average number of common shares outstanding of 356,087,960 and 350,124,456, respectively (2023 - 346,587,960 and 341,640,463, respectively). Diluted loss per share did not include the effect of convertible debt, stock options, and warrants as they are anti-dilutive.

16. Subsequent event

On November 6, 2024, the Company announced that it has negotiated debt settlements with arm's length and non-arm's length creditors pursuant to which it will settle aggregate debt of \$2,349,623 in consideration for which it will issue an aggregate of 78,320,764 common shares at a deemed price of \$0.03 per share.